Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | XPA | P23025 | 8/20 | 0.53 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | APEX1 | P27695 | 2/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | GALK1 | P51570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19419927 | 0.86 | ESR2 (0.69) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8290360 | 0.86 | ESR2 (0.81) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8291240 | 0.81 | ESR2 (0.84) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8290432 | 0.80 | ESR2 (0.72) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8291360 | 0.78 | ALDH1A1 (0.59) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL13708915 | 0.76 | ESR2 (0.62) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8291312 | 0.76 | KMT2A (0.72) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL8291279 | 0.76 | ESR2 (0.66) | ESR2ALDH1A1XPAKDM4EHPGD | |
| SCHEMBL12311905 | 0.75 | ESR2 (0.78) | ESR2ALDH1A1SMN1; SMN2XPAGSK3A | |
| SCHEMBL14584108 | 0.73 | ESR2 (0.62) | ESR2ALDH1A1XPAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | ESR2 806/4885ALDH1A1 545/4885SMN1; SMN2 595/4885 |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | MCL1, BCL2, BCL2L1 | ESR2 2704/4885ALDH1A1 2862/4885SMN1; SMN2 2677/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | ESR2 819/4885ALDH1A1 194/4885SMN1; SMN2 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.